The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Main Study: Percentage of Participants With Best (Overall) Objective Response
Timeframe: From Cycle 1 Day 1 up to 6 years 2 months
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Metformin Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Midazolam Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Midazolam Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Metformin Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Metformin Alone or in Combination With Erdafitinib
Timeframe: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)